# Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

> **NCT02296905** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** ABT-493
- **DRUG:** ABT-530

## Key facts

- **NCT ID:** NCT02296905
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296905, "Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02296905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*